Study guide

12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacist Licensure & Reciprocity

1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement

2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios

2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles

3 Chapter 3: Prescriptive Authority & Practitioner Categories

3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members

4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR

5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements

5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing

6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling

6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)

7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose

7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)

8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping

8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)

9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety

9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs

10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution

10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution

11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>

11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy

12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

Key Takeaways Explain This Topic AI

Protected Health Information (PHI) encompasses all individually identifiable health data held or transmitted by a covered entity in any medium (electronic, paper, or oral).

Pharmacies may disclose PHI for Treatment, Payment, and Health Care Operations (TPO) without explicit patient authorization, but non-TPO disclosures require written patient authorization.

Under the Minimum Necessary Rule, covered entities must limit PHI access and disclosure to the least amount necessary to accomplish the intended purpose (except for direct treatment disclosures between healthcare providers).

Business Associate Agreements (BAAs) must be executed with all third-party vendors (cloud software, shredding services, PBMs) who access, transmit, or store PHI on behalf of the pharmacy.

For PHI breaches affecting 500 or more individuals, covered entities must notify affected individuals, major media outlets, and the HHS Secretary without unreasonable delay and no later than 60 calendar days following discovery.

Last updated: July 2026

  • 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols
  • HIPAA Framework & Protected Health Information (PHI)

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) , enhanced by the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009 and the 2013 HIPAA Omnibus Rule, establishes national standards to protect sensitive patient health data.

Protected Health Information (PHI) Defined

Protected Health Information (PHI) includes any individually identifiable health information created, received, maintained, or transmitted by a covered entity (e.g., pharmacy, hospital, physician practice) or business associate, in any form or medium (paper, electronic, or oral). PHI covers past, present, or future physical or mental health conditions, provision of healthcare, or payment for healthcare.

PHI encompasses 18 explicit statutory identifiers when coupled with health data, including:

  • Patient full name, street address, zip code, and dates (birth, admission, discharge)
  • Telephone/fax numbers, email addresses, and Social Security Numbers (SSN)
  • Medical record numbers, health plan beneficiary numbers, and prescription numbers
  • Biometric identifiers (fingerprints), full-face photographic images, and device serial numbers
  • Permissible Disclosures: Treatment, Payment & Operations (TPO)

Covered entities may use and disclose PHI without prior written patient authorization for Treatment, Payment, and Health Care Operations (TPO) :

Treatment : Providing, coordinating, or managing healthcare services among providers. Examples include transferring a prescription to another pharmacy, consulting a prescriber regarding a drug interaction, or counseling a patient.

Payment : Obtaining reimbursement for healthcare services. Examples include submitting electronic claims to third-party pharmacy benefit managers (PBMs), verifying insurance eligibility, and conducting coverage audits.

Health Care Operations : Administrative, financial, legal, and quality-improvement activities. Examples include internal quality assurance audits, pharmacy technician training, regulatory compliance reviews, and legal defense.

Non-TPO Disclosures & Mandatory Written Authorization

Any use or disclosure of PHI outside of TPO requires a signed, explicit written authorization from the patient. Common scenarios requiring authorization include selling patient lists for commercial marketing, releasing records to life insurance companies, or providing data to prospective employers. Patients may revoke authorization in writing at any time.

The Minimum Necessary Standard & Safeguard Protocols

Under 45 CFR § 164.502(b), the Minimum Necessary Rule mandates that covered entities make reasonable efforts to limit the use, disclosure, or request of PHI to the minimum amount necessary to accomplish the intended purpose.

Minimum Necessary Rule APPLIES To: Minimum Necessary Rule EXEMPTIONS (Does NOT Apply):

Electronic billing claims submitted to PBMs Disclosures between healthcare providers for direct patient treatment

  • Healthcare operations & internal quality reviews Requests or disclosures made directly to the patient
  • Disclosures to third-party auditors or lawyers Disclosures authorized explicitly by written patient consent

External research requests and legal subpoenas Mandatory compliance disclosures to HHS / law enforcement under law

Security Rule Safeguards (Administrative, Physical & Technical)

Pharmacies must implement robust safeguards under the HIPAA Security Rule to protect electronic PHI (ePHI):

Administrative Safeguards : Conducting security risk assessments, assigning a Privacy and Security Officer, and training all workforce members annually.

Physical Safeguards : Computer screen privacy filters, locked file cabinets, restricted access to pharmacy server rooms, and secure document shredding bins.

Technical Safeguards : Role-based system access passcodes, automatic logoff timers, 256-bit data encryption at rest and in transit, and immutable audit log trails.

  • Notice of Privacy Practices (NPP) & Business Associate Agreements (BAA)
  • Notice of Privacy Practices (NPP)

Pharmacies must provide a written Notice of Privacy Practices (NPP) to every patient on the first day of service delivery. The NPP describes how PHI is used, patient privacy rights, and contact details for filing privacy complaints. The pharmacy must make a good-faith effort to obtain a signed, written acknowledgment of receipt from the patient. If the patient refuses to sign, the pharmacist must document the good-faith effort and the reason for refusal. Signed acknowledgments and NPP revisions must be retained for 6 years .

Business Associate Agreements (BAA)

A Business Associate (BA) is any third-party individual or entity that creates, receives, maintains, or transmits PHI on behalf of a covered entity. Common pharmacy BAs include software vendors, cloud hosts, claims clearinghouses, paper shredding companies, and legal consultants. Prior to granting access to PHI, the pharmacy must execute a legally binding Business Associate Agreement (BAA) . Under the HITECH Act, Business Associates are directly liable for civil and criminal penalties under HIPAA for unauthorized PHI disclosures.

Breach Notification Protocols & State Law Preemption

A breach is defined as the unauthorized acquisition, access, use, or disclosure of unencrypted PHI that compromises the security or privacy of the information. When a potential breach occurs, the pharmacy must perform a 4-Factor Risk Assessment :

The nature and extent of PHI involved (types of identifiers and likelihood of re-identification).

The unauthorized person who used the PHI or to whom disclosure was made.

Whether PHI was actually viewed or acquired.

The extent to which the risk to PHI has been mitigated (e.g., immediate destruction of misdirected mail).

Unless the assessment proves a low probability of compromise, breach notification is legally mandated:

Reporting Timelines Summary

Individual Written Notification : Required for ALL breaches without unreasonable delay and no later than 60 calendar days following discovery.

Breaches Affecting < 500 Individuals : Must be logged internally and reported electronically to the HHS Secretary within 60 days of the end of the calendar year .

Breaches Affecting ≥ 500 Individuals : Must notify affected individuals, major media outlets in the state/jurisdiction, and the HHS Secretary without unreasonable delay and no later than 60 calendar days after discovery.

State Privacy Law Preemption

HIPAA acts as a federal statutory baseline. Under federal preemption rules, if a state privacy law is more stringent (i.e., affords greater privacy protection to the patient or shorter breach notification timelines, such as 15 or 30 days), the state law supersedes federal HIPAA regulations. Specialized state laws protecting sensitive records (e.g., HIV status, mental health therapy notes, substance use disorder treatment under 42 CFR Part 2) almost universally preempt federal HIPAA baselines.

Loading diagram... HIPAA PHI Disclosure & Breach Notification Protocol